Intergeneric poliovirus recombinants for the treatment of malignant glioma
about
Interaction of nectin-like molecule 2 with integrin alpha6beta4 and inhibition of disassembly of integrin alpha6beta4 from hemidesmosomesProfile of Eckard Wimmer. Interview by Sujata GuptaCis-acting RNA elements in human and animal plus-strand RNA virusesInhibition of cell movement and proliferation by cell-cell contact-induced interaction of Necl-5 with nectin-3Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradicationCD155/PVR plays a key role in cell motility during tumor cell invasion and migrationTherapeutic Use of Native and Recombinant EnterovirusesReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataOncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyImmunotherapy for primary brain tumors: no longer a matter of privilegeOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesNuclear proteins hijacked by mammalian cytoplasmic plus strand RNA virusesRecruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to alpha(v)beta3 integrin-containing membrane microdomainsNecl-5/poliovirus receptor interacts in cis with integrin alphaVbeta3 and regulates its clustering and focal complex formationCellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice.Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells.Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.A predicted secondary structural domain within the internal ribosome entry site of echovirus 12 mediates a cell-type-specific block to viral replication.A nonpolio enterovirus with respiratory tropism causes poliomyelitis in intercellular adhesion molecule 1 transgenic mice.Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiformeExpression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog.Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.Oncolytic viruses as therapeutic agents.MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirusEfficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sitesActivity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3' nontranslated region.Oncolytic polio virotherapy of cancerThe Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis.Nectin and nectin-like molecules: biology and pathology.Oncolytic adenoviruses for treatment of brain tumours.RNA viruses as virotherapy agents.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.
P2860
Q24336974-DAADB506-D772-4E70-B218-17B63DA5B87FQ24624402-0E29DF91-7838-4C76-976B-B83C7C751F60Q24649975-19FF947C-EBCB-4941-9CA3-0BD13EBAFDB4Q24679516-D5EF6941-1BC5-40CE-9DC1-DDCD2E6EBEE5Q24683132-9DB15F58-5F37-43C2-88A6-C74654A7514DQ24805403-6EFCB170-7974-4B5D-8B9A-579AC2BACD8AQ26767082-07FD9F23-B959-4FE5-BD49-9DB1B27634ACQ26801501-D249877A-82B0-4EDB-8DCB-FF9B3E6B3384Q26998111-381AE6A4-3014-40B3-B449-B81E54B87305Q27002510-DC428ADD-CB26-4B9A-80F1-C1E74A0A0502Q27007519-B1C0A0E1-7319-4747-A56B-5FE599A98515Q28083735-75775838-580B-48A8-82FD-089DF333D7E7Q28205394-4BD8D3C3-C077-498F-961D-9460A924C8E3Q28298607-B7D7BEED-B0A6-4AB5-861F-330A6DDD2215Q30395978-DDAA1DE2-1BDF-4997-80E6-78B2FB29332DQ30402088-63967BAC-7C18-4895-A80A-6F687CFDEE8CQ33523284-54C346DB-D392-455D-AF4C-A593CED4AFDFQ33780536-CEE37539-4BDA-46E2-82B3-726049B5B458Q33780697-337066A4-4F42-4CF8-8882-C50E5E277BADQ33797119-EFE9AFF7-CF23-433E-A1A7-337E4914ED84Q33843227-819483CD-0CA5-471F-B9E1-E5A2F516C4A4Q33981201-717912F2-601A-4E33-8A57-25C66E8553E9Q34105106-03A11224-3AE6-4B5E-8AE2-54BB92598097Q34126107-5B1E2326-B401-4423-9DC2-33D3FF3E128AQ34133011-5B693D46-C790-4192-9C42-F5C4A6200324Q34225918-153F8B47-23E2-4CBC-830F-3505D6C23D07Q34297058-0499BAE4-97DC-4D34-911C-0B527F9EB6C1Q34329548-DA7A0E04-F885-4E42-9F65-0E6FFB8A50C7Q34343725-689FB2E9-346D-4C94-9517-787918B1E1BAQ34343768-ED271857-BD2B-4A92-906C-BBC2E564A171Q34361592-F9C6499C-38AC-4178-96D8-DA5A28718D83Q34391227-FF240AD5-2F6B-4500-B1F7-B1D99EB0C475Q34425385-A7E663E8-82A5-4F3D-8B3E-C5E63FE04D94Q34553267-555E7FC6-C073-4F58-AE3A-FEE67373ACB8Q34594574-67B9D36F-693C-4CA9-B04A-AE458386978CQ34594617-CB8D20A9-8E1A-45E4-828A-733B5D918AEAQ34682226-41FD8D2C-87B5-43E5-AB17-E5DC470ED16DQ35040863-B298367A-02BD-44AD-ACFE-6FBA5BDBAB70Q35043090-81DCFB54-8BC5-43EF-8A02-3E6E1556998CQ35043106-8BB2DC54-A9BD-4EA5-8F95-C669E3FF501A
P2860
Intergeneric poliovirus recombinants for the treatment of malignant glioma
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@ast
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@en
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@nl
type
label
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@ast
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@en
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@nl
prefLabel
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@ast
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@en
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@nl
P2093
P2860
P356
P1476
Intergeneric poliovirus recombinants for the treatment of malignant glioma
@en
P2093
P2860
P304
P356
10.1073/PNAS.97.12.6803
P407
P577
2000-06-06T00:00:00Z